The company's model is not AI drug discovery. Instead, they in-license assets that already have clinical data (Phase 1 or 2) and apply their AI platform to accelerate the drug development process. They identify development, not discovery, as the primary bottleneck in modern pharma.

Neurvati's model bypasses early-stage discovery risk by requiring assets to have 'peri-proof-of-concept' data (e.g., Phase 1b/2a) in humans. This focus on clinically de-risked programs with demonstrated biological activity and safety allows them to concentrate on late-stage development and execution.

To build investor confidence in the high-risk neuroscience field, Neurocrine employs a dual strategy. It highlights its own proven track record while simultaneously de-risking its pipeline by targeting biological pathways already validated by competitors, aiming to create superior, best-in-class medicines rather than pursuing unproven science.

In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.

Autobahn Therapeutics avoids the high failure rate of novel CNS targets. Instead, their strategy combines a biologically validated mechanism (thyroid hormone's effect on depression) with a proprietary prodrug platform that solves its historical limitation—peripheral side effects. This creates a rare combination of a de-risked target and strong IP.

Syndax bypasses the lengthy initial lab phase by in-licensing promising science from external sources. This allows their internal experts to focus directly on clinical development in areas of high unmet medical need, a key strategy behind getting two drug approvals in two years.

By focusing on metabolic pathways implicated in CNS disorders by human genetics, Leal can work with well-understood enzymes and targets. This simplifies the development process compared to pursuing novel, poorly understood CNS-specific pathways, providing a clearer path to drug development.

Neurocrine mitigates the high risk of its late-stage psychiatry programs, which have uncertain outcomes until Phase 3, by investing in an obesity asset. This program offers the ability to see clear efficacy signals in early Phase 1B trials, providing faster data for decision-making and balancing portfolio risk and cost.

Acquiring a Phase 1-complete drug is only the first step. Tortugas Neuroscience creates value by redirecting these assets into novel indications. They pivoted a neurosteroid toward tinnitus after seeing compelling external data, targeting an unmet need where the drug's mechanism could treat the entire syndrome.